Introduction: The TORCH (Tarceva or Chemotherapy) trial randomized patients with
advanced non–small-cell lung cancer to first-line erlotinib followed by second-line …

7018 Background: Erlotinib (Tarceva) prolongs survival in previously treated NSCLC pts
(ASCO 2004). In the palliative setting, assessing symptoms and quality of life (QOL) is also …

Purpose This report describes the quality of life (QOL) findings of a randomized placebo
controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with …

Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …

INTRODUCTION: Maintenance therapy can delay progression and prolong survival in
metastatic non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative …

Purpose In advanced non-small cell lung cancer (NSCLC), progressive disease burdens
patients considerably. Second-line (2L) chemotherapy improves survival marginally but …

7168 Background: Elderly patients derive survival benefit but significant toxicity from
chemotherapy for NSCLC. Erlotinib is associated with reasonable toxicity and has a survival …

Background: Three different tyrosine kinase inhibitors have been approved as first-line
therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non …

Health-related quality of life (HRQoL) is increasingly recognized as an important outcome in
the treatment of advanced non-small-cell lung cancer (NSCLC). This article reviews HRQoL …

Background This report describes quality of life (QoL) findings of a randomized study
comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated non-small …